<DOC>
	<DOCNO>NCT00962780</DOCNO>
	<brief_summary>The study evaluate safety , tolerability immunogenicity 13-valent pneumococcal conjugate vaccine ( 13vPnC ) HIV-infected subject 6 year age old previously immunize pneumococcal vaccine . All subject receive 3 dos 13vPnC 1 dose 23-valent pneumococcal polysaccharide vaccine ( 23vPS ) , dose give approximately 1 month apart .</brief_summary>
	<brief_title>Safety Immunogenicity 13-Valent Pneumococcal Conjugate Vaccine ( 13vPnC ) HIV-Infected Subjects 6 Years Age Older Who Are Naive Pneumococcal Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Human immunodeficiency virus ( HIV ) infect subject age 6 year old Viral load &lt; 50,000 copies/mL CD4+ T cell count &gt; = 200/uL within 6 month study vaccination Receiving stable highly active antiretroviral therapy ( HAART ) currently receive antiretroviral therapy No previous vaccination pneumococcal vaccine Subject parent/legal guardian able complete electronic diary Acquired immune deficiency syndrome ( AIDS ) time enrollment Current illicit substance and/or alcohol abuse History active chronic viral hepatitis Previous anaphylactic reaction vaccine vaccinerelated component Serious chronic disorder include metastatic malignancy endstage renal disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>vaccine</keyword>
	<keyword>13-valent pneumococcal conjugate vaccine</keyword>
	<keyword>23-valent pneumococcal polysaccharide vaccine</keyword>
	<keyword>human immunodeficiency virus</keyword>
</DOC>